leisure time -WSS

leisure time

author：focus 2025-09-07 14:11:40 - browse：5

An illustrated portrait of Eli Lilly's David Ricks and Skovronsky – biotech and pharma coverage from STAT — Eli Lilly CEO David Ricks (left) and Chief Scientific Officer Daniel S. Skovronsky Molly Ferguson for STAT

The partnership that would shape Eli Lilly into one of the biggest success stories in the pharmaceutical industry began with conversations around a relatively minor acquisition.

At the time, David Ricks was running Lilly’s U.S. business and was part of the team charged with evaluating Avid Radiopharmaceuticals, which Lilly would go on to purchase in 2010 for a paltry $300 million — couch change for a multibillion-dollar firm. But what struck Ricks was not the company’s technology, for imaging Alzheimer’s plaques, but Avid’s CEO, Daniel S. Skovronsky.

“Dan’s different,” Ricks told STAT. “I had this sense immediately. Some people get in biotech for the cha-ching.” Skovronsky turned out to be a secret weapon. Within six months, Ricks had been promoted to run Lilly’s biomedicine unit and Skovronsky was working for him.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Elisabeth Bik tackles the widespread issue of research misconduct

explore

focus

WSS

Change Healthcare cyberattack shows risk of industry consolidation

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

GSK Flovent asthma inhalers replaced by authorized generics

Doctor of U.S. President Joe Biden says he is fit for duty

Burning questions for the 2024 JPM Healthcare Conference

Childhood vaccination ad campaign launches in the U.K.

entertainment

leisure time

focus

United colonoscopy coverage change 'may cost lives,' doctors say

U.K. sequencing study surfaces new findings about tumor DNA

New air purifier tech could be key to improving indoor air quality

The biotech scorecard for Q1: 17 stock

Moonlake's readout produced a cash windfall. Risks remain

Burning questions for the 2024 JPM Healthcare Conference

After affirmative action ruling, medical educators look to 'holistic review'

Goldman Sachs launches $650M fund for life science investments

Duchenne breakthrough therapy leaves behind pioneering families

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

hotspot

JPM: CVS says Medicare Advantage patients are impacting profits

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

JPM: CVS says Medicare Advantage patients are impacting profits

Study fuels hope CAR

Feng Zhang, Grail founder join forces on new gene editing startup

Wikipedia

explore

focus

hotspot